

#21

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Roger W. Roeske

Serial No.: 08/480,494

Filed: June 7, 1995

For: *LHRH ANTAGONIST PEPTIDES*

Attorney Docket No.: PPI-007

Group Art Unit: T8T1

Examiner: Borin, M.

RECEIVED

AUG 20 1997

MATRIX CUSTOMER
SERVICE CENTER

VIA HAND DELIVERY

Assistant Commissioner for Patents
Washington, D.C. 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicant and his agent are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A full copy of each cited publication is enclosed.

With regard to reference DL, which is in German, Applicant's understanding of the relevance of this document is based on the English language abstract provided on the first page of the document, which discloses LHRH antagonists of a general formula shown in the abstract.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the


merits issues in this application bearing a mailing date prior to the date of this Second Supplemental Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR 1.17(p) to our Deposit Order Account No. 12-0080.

In view of the large number of references that have been made of record in this application by way of 1) the Information Disclosure Statement dated March 5, 1996; 2) the Supplemental Information Disclosure Statement dated April 11, 1997; and 3) the instant Second Supplemental Information Disclosure Statement, Applicant would like to draw the Examiner's attention in particular to the following cited references:

- 1) U.S. Patent No. 5,110,904 (Reference BV);
- 2) U.S. Patent No. 5,300,492 (Reference CC);
- 3) U.S. Patent No. 5,413,990 (Reference CF);
- 4) U.S. Patent No. 4,800,191 (Reference DA);
- 5) U.S. Patent No. 5,198,533 (Reference DB); and
- 6) U.S. Patent No. 5,491,217 (Reference DF).

If a telephone conversation with Applicant's Agent would expedite the prosecution of the above-identified application, the examiner is urged to call the undersigned at (617) 227-7400.

Respectfully submitted,



Catherine J. Kara
Reg. No. 41,106
Agent for Applicant

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
(617) 227-7400

Date: August 19, 1997

LAHIVE & COCKFIELD, LLP

JOHN A. LAHIVE, JR. (1928-1997)
W. HUGO LIEPMANN
JAMES E. COCKFIELD
THOMAS V. SMURZYNSKI
RALPH A. LOREN
THOMAS J. ENGELLENER
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
PAUL LOUIS MYERS, Ph.D.
ELIZABETH A. HANLEY
MICHAEL I. FALKOFF
JOHN V. BIANCO
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
JANE E. REMILLARD
MARK A. KURISKO
JEAN M. SILVERI
PETER J. RAINVILLE
CHARLES ERIC SCHULMAN
FAUSTINO A. LICHAUICO

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahcoc.com

SCOTT D. ROTHENBERGER, Ph.D.
DAVID A. LANE, JR.
THOMAS P. GRODT

OF COUNSEL
JEREMIAH LYNCH
LAWRENCE E. MONKS
WILLIAM A. SCOFIELD, JR.

TECHNICAL SPECIALISTS
CATHERINE J. KARA, Ph.D.
MARK D. RUSSETT
IVANA MARAVIC-MAGOVCEVIC, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
SONIA K. GUTERMAN, Ph.D.
DIANA M. COLLAZO, Ph.D.
JASSIR K. SAGOO, Ph.D.
DEBRA J. MILASINIC, Ph.D.
MARIA C. LACCOTRIPE, Ph.D.
LAURANNE S. BUTLER

August 19, 1997

VIA HAND DELIVERY

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

Re: U.S. Patent Application Serial No. 08/480,494
LHRH ANTAGONIST PEPTIDES
by: Roger W. Roeske
Filed: June 7, 1995
Our Ref. No.: PPI-007

MATRIX CUSTOMER
SERVICE CENTER

Dear Sir:


I enclose herewith for filing in the above-identified application the following:

1. Second Supplemental Information Disclosure Statement;
2. PTO Form 1449;
3. Full copies of references (7) cited in PTO Form 1449; and
4. Postcard Receipt.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Catherine J. Kara
Registration No. 41,106
Agent for Applicant